Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineA Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia

SEP-363856, a non-D2-receptor binding antipsychotic, reduced the PANSS total score from baseline more than the placebo in this 4-week experiment comprising individuals with acute exacerbations of schizophrenia. Longer and larger trials are required to confirm SEP-363856’s effects and side effects as well as its efficacy in comparison to other medications currently used to treat schizophrenia patients.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form